

Mary V. Seeman, Pertinent Publications

Seeman, M.V., Denber, H.C.B., Goldner, F.: Paradoxical effects of phenothiazines. *Psychiatr. Q.* 42(1):90-103 (1968). doi: 10.1007/BF01563955

<https://www.ncbi.nlm.nih.gov/pubmed/4384921>

Seeman, M.V.: Management of the schizophrenic patient. *Can. Med. Assoc. J.* 120(9): 1097-1104 (1979).

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1819293/>

Ezrin-Waters, C., Seeman, M.V., Seeman, P.: Tardive dyskinesia in schizophrenic outpatients: Prevalence and significant variables. *J. Clin. Psychiatry.* 42:16-22 (1981).

<https://www.ncbi.nlm.nih.gov/pubmed/6109715>

Seeman, M.V.: Tardive dyskinesia: Two-year recovery. *Comprehensive Psychiatry.* 22: 189-192 (1981).

doi:10.1016/0010-440X(81)90069-9 <https://www.ncbi.nlm.nih.gov/pubmed/6111416>

Seeman, M.V., Patel, J., Pyke, J.: Tardive dyskinesia with Tourette-like syndrome. *J. Clin. Psychiatry.* 42:357-358 (1981). Tardive dyskinesia with Tourette-like syndrome - Reply *J. Clin. Psychiatry.* 43:215 (1982). <https://www.ncbi.nlm.nih.gov/pubmed/6944306>

Seeman, M.V.: Pharmacological features and the effects of neuroleptics. *Can. Med. Assoc. J.* 125: 821-826 (1981). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1862699/>

Hoffman, B.F., Seeman, M.V.: The management of neuroleptic-induced CNS effects. *Can. Family Physician.* 27:1615-1624 (1981).

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2306233/>

Pyke, J., Seeman, M.V.: Neuroleptic-free intervals in the treatment of schizophrenia. *Am. J. Psychiatry.* 138(12):1620-1621 (1981). doi: 10.1176/ajp.138.12.1620

<http://www.ncbi.nlm.nih.gov/pubmed/6118068>

Seeman, M.V.: Interaction of sex, age, and neuroleptic dose. *Comprehensive Psychiatry.* 24:125-128 (1983). doi:10.1016/0010-440X(83)90100-1 <https://www.ncbi.nlm.nih.gov/pubmed/6133698>

Seeman, M.V.: Schizophrenic men and women require different treatment programs. *J Psychiatr Treatment Evaluation* 5(2-3):143-148 (1983).

[https://www.researchgate.net/publication/232523807_Schizophrenic_men_and_women_require_diffe
rent_treatment_programs](https://www.researchgate.net/publication/232523807_Schizophrenic_men_and_women_require_different_treatment_programs)

McGee, H., Seeman, M.V., Deck, L.H.: Fluspirilene neuroleptic depot injections and indurations. *Can. J. Psychiatry.* 28:379-381 (1983). doi: 10.1177/070674378302800510

<https://www.ncbi.nlm.nih.gov/pubmed/6627197>

Seeman, M.V.: Neuroleptic response: Predictive clinical clues. *International Drug Therapy Newsletter. Psychopharm. Review.* 19(1):1-3 (1984).

https://journals.lww.com/psychopharmrev/Citation/1984/01000/NEUROLEPTIC_RESPONSE__PREDICTIVE_CLINICAL_CLUES_.1.aspx

Seeman, M.V.: Clinical and demographic correlates of neuroleptic response. *Can. J. Psychiatry.* 30:243-245 (1985). Reply to letter: *Can. J. Psychiatry.* 31:600 (1986). doi: 10.1177/070674378503000404 <https://www.ncbi.nlm.nih.gov/pubmed/2861886>

Seeman, M.V., Seeman, P.: Molecular psychiatry, receptor density, and receptor sensitivity states. *Integrative Psychiatry.* 4(1): 41-43 (1986). <https://psycnet.apa.org/psycinfo/1987-31491-001>

Seeman, M.V.: Neuroleptic prescription for men and women. *Social Pharmacol.* 3: 219-236 (1989). https://www.researchgate.net/publication/233911315_Neuroleptic_prescription_for_men_and_women

Fornazzari, X., Grossman, H., Thornton, J., Seeman, M.V.: Tardive dyskinesia: a five year follow-up. *Can. J. Psychiatry.* 34:700-703 (1989). doi: 10.1177/070674378903400713 <https://www.ncbi.nlm.nih.gov/pubmed/2572317>

Seeman, M.V., Lang, M.: The role of estrogens in schizophrenia gender differences. *Schizophrenia Bull.* 16:185-194 (1990). doi: 10.1093/schbul/16.2.185 <https://pubmed.ncbi.nlm.nih.gov/2197713/>

Seeman, P., Ohara, K., Ulpian, C., Seeman, M.V., Jellinger, K., Van Tol, H.H.M., Niznik, H.B.: Schizophrenia: Normal sequence in the dopamine D2 receptor region that couples to G-proteins. DNA polymorphisms in D2. *Neuropsychopharmacology.* 8:137-142 (1993). doi:10.1038/npp.1993.15 <https://www.ncbi.nlm.nih.gov/pubmed/8471125>

Zaretsky, A., Rector, N.A., Seeman, M.V., Fornazzari, X.: Current cannabis use and tardive dyskinesia. *Schizophrenia Res.* 11(1): 3-8 (1993). doi: 10.1016/0920-9964(93)90032-E <http://www.ncbi.nlm.nih.gov/pubmed/7905284>

Dale, R., Langdon, M., Seeman, M.V.: Reducing the dose of depot neuroleptic in stable schizophrenia. *J. Psychiatr. Neurosci.* 19: 278-281(1994). <https://www.ncbi.nlm.nih.gov/pubmed/7918349>

Seeman, P., Ulpian, C., Chouinard, G., Van Tol, H.H.M., Dwosh, H., Lieberman, J.A., Siminovitch, K., Liu, I.S.C, Waye, J., Voruganti, P., Hudson, C., Serjeant, G.R., Masibay, A.S., Seeman, M.V.: Dopamine D4 receptor variant, D4glycine194, in Africans, but not in Caucasians: No association with schizophrenia. *Am. J. Med. Genetics.* 54:384-390 (1994). <https://www.ncbi.nlm.nih.gov/pubmed/7726213>

Turrone, P., Seeman, M.V., Silvestri, S.: Estrogen receptor activation and tardive dyskinesia. *Can. J. Psychiatry.* 45:288-290 (2000). doi: 10.1177/070674370004500310 <http://www.ncbi.nlm.nih.gov/pubmed/10779888>

Silvestri, S., Seeman, M.V., Negrete, J.C., Houle, S., Shammi, C.M, Remington, G.J., Kapur, S., Zipursky, R.B., Wilson, A.A., Christensen, B.K., Seeman, P.: Increased dopamine D2 receptor

binding after long-term treatment with antipsychotics in humans: a clinical PET study. *Psychopharmacology*. 152(2):174-180 (2000). doi: 10.1007/s002130000532
<http://www.ncbi.nlm.nih.gov/pubmed/11057521>

Parker, V., Wong, A.H.C., Boon, H.S., Seeman, M.V.: Adverse reactions to St. John's wort. *Can. J. Psychiatry*. 46(1):77-79 (2001). doi: 10.1177/070674370104600112
<https://www.ncbi.nlm.nih.gov/pubmed/11221494>

Seeman, M.V.: Clinical trials in psychiatry: Do results apply to practice? *Can. J. Psychiatry*. 46(4):352-355 (2001). doi: 10.1177/070674370104600407
<https://pubmed.ncbi.nlm.nih.gov/11387792/>

Turenne, S.D., Seeman, M.V., Ross, B.M.: An animal model of nicotinic- acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. *Schizophrenia Research*. 50:191-197 (2001). <http://www.ncbi.nlm.nih.gov/pubmed/11439240>

Turrone, P., Kapur, S., Seeman M.V., Flint, A.: Elevation of prolactin levels by atypical antipsychotics. *Am. J. Psychiatry*. 159(1):133-135 (2002). doi: 10.1176/appi.ajp.159.1.133
<http://ajp.psychiatryonline.org/cgi/content/full/159/1/133>

Grigoriadis, S., Seeman, M.V.: The role of estrogen in schizophrenia: Implications for schizophrenia practice guidelines for women. *Can. J. Psychiatry*. 47(5):437-442 (2002). doi: 10.1177/070674370204700504 Reprinted: *Focus*. 4:134-139 (2006).
<https://www.ncbi.nlm.nih.gov/pubmed/12085678>

Ross, B.M., Brooks, R., Lee, M., Kalasinsky, K., Seeman, M.V., Fletcher, P.J., Turenne, S.D.: Cyclooxygenase inhibitor modulation of dopamine-related behaviours. *Eur. J. Pharmacology* 23:450:141-151 (2002). doi: 10.1016/S0014-2999(02)02104-0
<https://www.ncbi.nlm.nih.gov/pubmed/12206852>

Seeman, M.V., Seeman, P.: Choosing an antipsychotic and why. *Medscape CME*. Sept 16, 2002.
<http://www.medscape.org/viewarticle/441135>

Zhang-Wong, J.H. Seeman, M.V.: Antipsychotic drugs, menstrual regularity and osteoporosis risk. *Archives of Women's Mental Health* 5:93-98 (2002). doi: 10.1007/s00737-002-0002-4
<http://www.ncbi.nlm.nih.gov/pubmed/12510211>

Wong, J., Seeman M.V., Shapiro, H.: Case report: raloxifene in postmenopausal women with psychosis: preliminary findings. *Am. J. Geriatric Psychiatry*. 11:697-698 (2003). doi: 10.1176/appi.ajgp.11.6.697 <http://www.ncbi.nlm.nih.gov/pubmed/14609815>

Silvestri, S., Negrete, J.C., Seeman, M.V., Shammi, C.M., Seeman, P.: Does nicotine affect D2 receptor upregulation? A case-control study. *Acta Psychiatr. Scand*. 109:313-317 (2004). doi: 10.1111/j.1600-0447.2004.00293.x
<http://www.ncbi.nlm.nih.gov/pubmed/15008806>

Ross, B.M., Hughes, B.H., Turenne, J., Seeman M.V., Warsh, J.J.: Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry. *European*

Neuropsychopharmacol. 14:191-197 (2004). doi:10.1016/S0924-977X(03)00145-7
<http://www.ncbi.nlm.nih.gov/pubmed/15056478>

Seeman, M.V.: Gender differences in the prescribing of antipsychotic drugs. *Am. J. Psychiatry.* 161:1324-1333 (2004). doi: 10.1176/appi.ajp.161.8.1324
<https://pubmed.ncbi.nlm.nih.gov/15285956/>

Chaves, A.C., Seeman, M.V.: Sex selection bias in schizophrenia antipsychotic trials. *J. Clin. Psychopharmacol.* 26:489-494 (2006). doi:10.1097/01.jcp.0000236652.78168.ee
<http://www.ncbi.nlm.nih.gov/pubmed/16974190>

Seeman, M.V.: Antipsicóticos: factores que contribuyen a la aparición de eventos adversos en las mujeres. *Claves de Psiquiatría.* 2(1):3-5 (2007).
http://www.siicsalud.com/pdf/clavespsiquiatria2_1.pdf

Seeman, M.V.: Do the causal paths to psychosis converge on D2High? *Clinical Schizophrenia & Related Psychoses.* 2(1):98-99 (2008). doi: 10.3371/CSRP.2.1.9
https://www.researchgate.net/publication/235409766_Do_the_causal_paths_to_psychosis_converge_on_D2High

Seeman, M.V.: Secondary effects of antipsychotics: Women at greater risk than men. *Schizophr. Bull.* 35: 937-948 (2009). doi:10.1093/schbul/sbn023
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728808/> Spanish version. *Selección de Artículos* 5(2):92-103 (2010)
<http://www.jc-edicionesmedicas.com/revistas/numero-actual>

Seeman, M.V., Clodman, D., Remington, G.: Transient tardive dystonia: Overview and case presentation. *J. Psychiatric Practice* 14 (4):251-257 (2008).
doi:10.1097/01.pra.0000327317.34647.28 <http://www.ncbi.nlm.nih.gov/pubmed/18664896>

Seeman, M.V.: Schizophrenia: Women bear a disproportionate toll of antipsychotic side effects. *J. Am. Psychiat. Nurses Assoc.* 16: 21-29 (2010). doi:10.1177/1078390309350918
<http://www.ncbi.nlm.nih.gov/pubmed/21659259>

Seeman, M.V.: Sleepwalking: A possible side effect of antipsychotic medication. *Psychiatr. Q.* 82:59-67 (2011). doi:10.1007/s11126-010-9149-8
<http://www.ncbi.nlm.nih.gov/pubmed/20734137>

Seeman, P., Seeman, M.V.: Schizophrenia and the supersensitive synapse. *Neuropsychiatry.* 1: 233-242 (2011). doi: 10.2217/npv.11.18
<http://www.futuremedicine.com/doi/abs/10.2217/npv.11.18>

Seeman, M.V.: Antipsychotic-induced somnolence in mothers with schizophrenia. *Psychiatr. Q.* 83:83-89 (2012). doi:10.1007/s11126-011-9185-z
<http://www.ncbi.nlm.nih.gov/pubmed/21739299>

Seeman, M.V.: Antipsychotic-induced amenorrhea. *J. Ment. Health* 20:484-491 (2011). doi:10.3109/09638237.2011.586741 <http://www.ncbi.nlm.nih.gov/pubmed/21942684>
<http://informahealthcare.com/eprint/XeU6G6pgcxHvJCYydTB/full>

Seeman, M.V.: Antipsychotics and physical attractiveness. *Clinical Schizophrenia and Related Psychoses*. 5:142-146C (2011). doi:10.3371/CSRP.5.3.4
<https://www.ncbi.nlm.nih.gov/pubmed/21983498>

Seeman, M.V.: Treating schizophrenia at the time of menopause. *Maturitas*. 72(2):117-120 (2012). doi:10.1016/j.maturitas.2012.03.008 <http://www.ncbi.nlm.nih.gov/pubmed/22503514>

Seeman, M.V.: Clinical interventions for women with schizophrenia: pregnancy. *Acta Psychiatrica Scand*. 127(1):12-22 (2013). doi:10.1111/j.1600-0447.2012.01897.x
<http://www.ncbi.nlm.nih.gov/pubmed/22715925>

Seeman, M.V., Seeman, N.: The meaning of antipsychotic medication to patients with schizophrenia. *J. Psychiatric Practice*. 18(5):338-348 (2012).doi: 10.1097/01.pra.0000419818.60505.95 <http://www.ncbi.nlm.nih.gov/pubmed/22995961>

Seeman, M.V.: Loss of libido in a woman with schizophrenia. *Am. J. Psychiatry*. 170(5):471-475 (2013). doi: 10.1176/appi.ajp.2012.12111475
<http://www.ncbi.nlm.nih.gov/pubmed/23632833>

Seeman, M.V., Seeman, P.: Is schizophrenia a dopamine supersensitivity reaction? *Prog. Neuropsychopharmacol. Biol. Psychiatry*. 48:155-160 (2014). doi: 10.1016/j.pnpbp.2013.10.003.
<http://www.ncbi.nlm.nih.gov/pubmed/24128684>

Kennedy, S.H, Giacobbe, P., Placenza, F.M., Hudson, C.J., Seeman, P., Seeman, M.V.: Depression treatment by withdrawal of short-term low-dose antipsychotic, a proof-of-concept randomized double-blind study. *J Affect Disord*. 166: 139-143 (2014).doi: org/10.1016/j.jad.2014.04.014
<http://www.ncbi.nlm.nih.gov/pubmed/25012422>

Hudson, C., Seeman, P., Seeman, M.V.: Parkinson's disease: low dose haloperidol increases dopamine receptor sensitivity and clinical response. *Parkinson's Dis*. Article ID 684973, 5 pages, (2014). doi.org/10.1155/2014/684973
<http://www.ncbi.nlm.nih.gov/pubmed/25506040>

Seeman, M.V.: Transient psychosis in women on clomiphene, bromocriptine, domperidone and related endocrine drugs. *Gynecological Endocrinology*. 31(10):751-754 (2015). doi: 10.3109/09513590.2015.1060957
<http://www.ncbi.nlm.nih.gov/pubmed/26291819>

Seeman, M.V.: Exercise and antipsychotic drugs. *J Patient Care* 2(2):114. (2016). doi: 10.4172/2573-4598.1000114
<https://www.omicsonline.org/open-access/exercise-and-antipsychotic-drugs-.php?aid=77688>

González-Rodríguez, A., Catalán, R., Penadés, R., Ruiz Cortés, V.B.N., Torra, M., Seeman, M.V., Bernardo, M.: Antipsychotic response worsens with postmenopausal duration in women with schizophrenia. *J. Clinical Psychopharmacology*. 36(6):580-587. (2016). doi:10.1097/JCP.0000000000000571 <https://www.ncbi.nlm.nih.gov/pubmed/27626286>

Brzezinski, A., Brzezinski-Sinai, N.A., Seeman, M.V.: Treating schizophrenia during menopause. *Menopause*. 24(5):582-588 (2017). doi: 10.1097/GME.0000000000000772 <https://www.ncbi.nlm.nih.gov/pubmed/27824682>

Seeman, M.V.: Antipsychotics, hypothermia, undressing, and death. *Global Journal of Medical and Clinical Case Reports*. 4(1):1-3. (2017). doi: 10.17352/2455- 5282.000032 <https://www.peertechz.com/articles/antipsychotics-hypothermia-undressing-and-death.pdf>

Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M.V., Correll, C.U., Carvalho, A.F.: Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. *Ther. Clin. Risk Manag.* 13:757-777 (2017). doi: 10.2147/TCRM.S117321 <https://pubmed.ncbi.nlm.nih.gov/28721057/>

González-Rodríguez, A., Bernardo, M., Penadés, R., Arias, B., Ruiz Cortés, V., Seeman, M.V., Catalán R.: Do FSH/LH ratio and gonadal hormone levels predict antipsychotic response in postmenopausal schizophrenia women? *Archives of Women's Mental Health*. 20(5): 613-620 (2017). doi: 10.1007/s00737-017-0757-2 <https://www.ncbi.nlm.nih.gov/pubmed/28702774>

Seeman, M.V.: Drawbacks of long-acting intramuscular antipsychotic injections. *Journal of Clinical and Practical Nursing*. 1(1):12-23 (2017). doi: JCPN-17-1562 <http://openaccesspub.org/jcpn/article/510>

Seeman, M.V.: Prescription drugs parents take: Consequences for children. *Scientific J Depression & Anxiety*. 1(1):8-13 (2017). <http://www.scireslit.com/Depression/SJDA-ID12.pdf>

Seeman, M.V.: Assessing the effects of antipsychotics on parenting. *Women's Health Bulletin*. 5(1):e13409 (2018). doi: 10.5812/whb.13409 <https://womenshealthbulletin.com/en/articles/13409.html>

Seeman, M.V.: Prevention of antipsychotic side effects in elderly populations. *J Mental Health and Aging*. 2(1):24-28. (2018). <https://www.alliedacademies.org/articles/prevention-of-antipsychotic-side-effects-in-elderly-populations-9502.html>

Seeman, M.V., Seeman N.L., Cho, J.A.: Worldwide preferences for natural remedies for "nervousness" and common colds. *J Psychiatry Brain Science*. 1(1):1-11. (2018). doi: 10.20900/jpbs.20180001 https://jpbs.hapres.com/htmls/JPBS_955_Detail.html

Seeman, M.V., González-Rodríguez A.: Use of psychotropic medication in women with psychotic disorders at menopause and beyond. *Curr Opin in Psychiatry*. 31(3):183-192. (2018). doi: 10.1097/YCO.0000000000000410 <https://www.ncbi.nlm.nih.gov/pubmed/29528895>

González-Rodríguez, A., Seeman, M.V.: Pharmacotherapy for schizophrenia in postmenopausal women. *Expert Opin Pharmacother.* 19(8):809-821. (2018). doi:10.1080/14656566.2018.1465563 <https://www.ncbi.nlm.nih.gov/pubmed/29676942>

González-Rodríguez, A., Seeman, M.V.: The association between hormones and antipsychotic use: a focus on postpartum and menopausal women. *Therapeutic Advances in Psychopharmacology.* 9: 2045125319859973. (2019). 20 pages. doi: 10.1177/2045125319859973 <https://www.ncbi.nlm.nih.gov/pubmed/31321026>

Seeman, M.V.: Antipsychotics during pregnancy: Pros and cons. *Open J Gynecol Obstet Research (OJGOR).*1:58-64. (2019). doi: 10.36811/ojgor.2019.110010 https://www.researchgate.net/publication/338222062_Antipsychotics_during_Pregnancy_Pros_and_Cons

González-Rodríguez, A., Seeman, M.V.: Gonadal and adrenal hormones implicated in antipsychotic response in postmenopausal women with schizophrenia and related disorders. *Current Trends in Endocrinology.* 10:47-54. (2019). <http://www.researchtrends.net/tia/abstract.asp?in=0&vn=10&tid=59&aid=6472&pub=2019&type=3>

Seeman, M.V.: Men and women respond differently to antipsychotic drugs. *Neuropharmacology.*163:107631 (2020). doi: 10.1016/j.neuropharm.2019.05.008 <https://www.ncbi.nlm.nih.gov/pubmed/31077728>

Seeman, M.V.: The gut microbiome and treatment-resistance in schizophrenia. *Psychiatric Quarterly.* 2020;91(1):127-136. doi: 10.1007/s1126-019-09695-4 <https://www.ncbi.nlm.nih.gov/31781943>

Seeman, M.V.: Medication-induced stuttering in psychiatric patients. *This Changed My Practice UBC.* Feb. 5, 2020. <http://secure.campaigner.com/csb/Public/show/ceu9-1qs98k--ojw2d-5kqgzu3>

González-Rodríguez, A., Labad, J., Seeman, M.V.: Antipsychotic-induced hyperprolactinemia in aging populations: Prevalence, implications, prevention and management. *Progress Neuropsychopharmacol Biol Psychiatry.* 101:109941 (2020) doi: 10.1016/j.pnpbp.2020.109941 <https://www.ncbi.nlm.nih.gov/pubmed/32243999>

González-Rodríguez, A., Guàrdia, A., Palao, D.J., Labad, J., Seeman, M.V.: Moderators and mediators of antipsychotic response in delusional disorder: further steps are needed. *World J Psychiatry;*10(4):34-45. (2020) doi: 10.5498/wjp.v10.i4.34 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203082/>

González-Rodríguez, A., Guàrdia, A., Álvarez, A., Betriu, M., Cobo, J., Acebillo, S., Monreal, J.A., Seeman, M.V., Palao, D., Labad, J.: Women with schizophrenia over the life span: health promotion, treatment and outcomes. *Int J Environ Public Health.* 17(15):E5594. (2020) doi:10.3390/ijerph17155594 <https://pubmed.ncbi.nlm.nih.gov/32756418/>

Seeman, M.V., Seeman, P.: In Memoriam: Oleh Hornykiewicz (1926-2020). International Network for the History of Neuropsychopharmacology. (2020). <https://inhn.org/biographies/in-memoriam-of-oleh-hornykiewicz-1926-2020-by-mary-and-philip-seeman.html>

Guàrdia, A., González-Rodríguez, A., Álvarez, A., Betriu, M., Seeman, M.V., Monreal, J.A., Palao, D., Labad, J. Therapeutic drug monitoring is useful when pharmacogenetic assessment is unavailable: case report of delusional disorder. *Psicosomatica y Psiquiátrica*.14:28-32. (2020). ISSN 2565-0564 https://psicosomaticaypsiquiatria.com/download/psicosom_psiquiatr_2020_14_28_32/?wpdmdl=5706&refresh=5f75b45b37b2e1601549403

Solmi, M., Bordini, L., Coccozza, S., Carvalho, A.F., Seeman, MV., Vieta, E., Dragioti, E., Fusar-Poli, P.: Aripiprazole monotherapy as transdiagnostic intervention for the treatment of mental disorders: an umbrella review according to TRANSD criteria. *European Neuropsychopharmacology*. 41:16-27. (2020). doi: 10.1016/j.euroneuro.2020.09.635. <https://pubmed.ncbi.nlm.nih.gov/33077324/>

Macêdo D.S., Sanders L.L.O., das Candeias R., de Freitas Montenegro C., de Lucena D.F., Chaves Filho A.J.M., Seeman M.V., Monte A.S.: G protein-coupled estrogen receptor 1 (GPER) as a novel target for schizophrenia drug treatment. *Schizophrenia Bulletin Open*, sgaa062. (2020). doi: 10.1093/schizbullopen/sgaa062 <https://academic.oup.com/schizbullopen/advance-articles>

Seeman, M.V., Seeman, P.: In memoriam: Oleh Hornykiewicz (1926-2020). International Network for the History of Psychopharmacology. 2020. https://inhn.org/fileadmin/user_upload/User_Uploads/INHN/Biographies/HORNYKIEWICZ_in_Memory_by_Seemans__1_.pdf

Seeman, P., Seeman, M.V.: The dopamine hypothesis of schizophrenia in historical perspective. International Network for the History of Neuropsychopharmacology. 2020. https://inhn.org/index.php?id=3722&utm_source=INHN+Members&utm_campaign=ac40760ac9-EMAIL_CAMPAIGN_2017_06_12_COPY_01&utm_medium=email&utm_term=0_3788e1c52f-ac40760ac9-23257925&goal=0_3788e1c52f-ac40760ac9-23257925

Seeman, M.V.: The gut microbiome and antipsychotic treatment response. *Behavioural Brain Res*. 396:112886. (2021). doi: 10.1016/j.bbr.2020.112886 <https://pubmed.ncbi.nlm.nih.gov/32890599/>

Seeman, M.V.: The pharmacodynamics of antipsychotic drugs in women and men. *Front Psychiatry*. 12: 650904 (2021). doi: 10.3389/fpsy.2021.650904 <https://pubmed.ncbi.nlm.nih.gov/33897500/>

Barrio, P., Seeman, M.V., González-Rodríguez A.: Alcohol and psychosis: a narrative review of the prevalence, clinical manifestations and management of alcohol-related psychotic symptoms. *Current Psychiatry Research and Reviews*. 17(2):72-80. (2021). doi: 10.2174/2666082217666210602111739 <https://www.eurekaselect.com/193778/article>

Seeman, M.V.: History of the dopamine hypothesis of antipsychotic action. *World Journal of Psychiatry*. 11(7):355-364. (2021). doi: 10.5498/wjpv.11.i7.355 <https://pubmed.ncbi.nlm.nih.gov/34327128/>

Seeman, M.V., González-Rodríguez, A.: Stratification by sex and hormone level when contrasting men and women in schizophrenia trials will improve personalized treatment. *J Personalized Medicine*. 11(9):929. (2021). doi: 10.3390/jpm11090929
<https://pubmed.ncbi.nlm.nih.gov/34575706/>

González-Rodríguez, A., Seeman, M.V., Monreal J.A.: Optimizing treatment of delusional disorder: new goals for a new era. *Current Topics in Pharmacology*. 25:61-68. (2021).
http://researchtrends.net/tia/article_pdf.asp?in=0&vn=25&tid=11&aid=6796
Seeman, M.V.: Philip Seeman and dopamine and schizophrenia. *Psicosomatica y Psiquiatria*. 18:11-13. (2021). doi: 10/PsicosomPsiquiatrnum1802 www.psicosomaticaypsiquiatria.com
https://scholar.google.com/scholar?start=10&q=seeman+mv&hl=en&as_sdt=0,5&as_ylo=2021

Guàrdia, A., González-Rodríguez, A., Seeman, M.V., Álvarez, A., Estrada, F., Acebillo, S., Labad, J., Monreal, J.A.: Dopamine, serotonin and structure/function brain defects as biological bases for treatment response in delusional disorder: a systematic review of cases and cohort studies. *Behavioral Science (Basel)*. 11(10):141. doi: 10.3390/bs11100141
<https://pubmed.ncbi.nlm.nih.gov/34677234/>

Seeman, M.V.: Philip Seeman's contributions to the story of schizophrenia. *Psychological Medicine*. 52(13):2401-2403. (2022). doi: 10.1017/S0033291721004803
<https://www.cambridge.org/core/journals/psychological-medicine/article/philip-seemans-contributions-to-the-story-of-schizophrenia/CACB15EACF7D84FEE16847576C99ECA>

Monreal, J.A., Duval, F., González-Rodríguez, A., Seeman, M.V.: Apomorphine probe: A synthesis of studies with implications for affective and psychotic disorders. *Current Trends in Endocrinology*. 12:35-41 (2021).
http://www.researchtrends.net/tia/title_issue.asp?id=59&in=0&vn=12&type=3

González-Rodríguez, A., Monreal, J.A., Seeman, M.V.: Factors influencing adherence to antipsychotic medications in women with delusional disorder: A narrative review. *Current Pharmaceutical Design*. 28(15):1282-1293 (2022). doi: 10.2174/1381612828666220310151625
<https://pubmed.ncbi.nlm.nih.gov/35272589/>

Novak, G., Seeman, M.V.: Dopamine, psychosis, and symptom fluctuation: A narrative review. *Healthcare*. 10(9), 1713. (2022). doi.org/10.3390/healthcare10091713
<https://pubmed.ncbi.nlm.nih.gov/36141325/>

González-Rodríguez, A., Monreal, J.A., Seeman, M.V.: The effect of menopause on antipsychotic response. *Brain Sciences*. 12(10): 1342. (2022). doi: 10.3390/brainsci12101342
<https://pubmed.ncbi.nlm.nih.gov/36291276/>

Silva, FERd, Cordeiro, R.C., Lima, CNdC, Vasconcelos, G.S., Monte, A.S., Sanders, L.L.O., Vasconcelos, S.M.M., de Lucena, D.F., Cruz, B.F., Seeman, M.V., Ribeiro F.M, Macedo, D.: Sex and the estrous-cycle phase influence the expression of G protein-coupled estrogen receptor 1 (GPER) in schizophrenia: translational evidence for a new target. *Research Square preprint*. (2022) doi.: 10.21203/rs.3.rs-2050344/v1 <https://europepmc.org/article/ppr/ppr548120>

González-Rodríguez, A., Monreal, J.A., Natividad, M., Seeman, M.V.: Seventy years of treatment of delusional disorder with antipsychotics: An historical perspective. *Biomedicines*. 10(12):3281. doi: 10.3390/biomedicines10123281 <https://pubmed.ncbi.nlm.nih.gov/36552037/>

González-Rodríguez, A., Seeman, M.V., Román, E., Natividad, M., Pagés, C., Ghigliazza, C., Ros, L., Monreal, J.A.: Critical issues in the management of agitation, aggression and end-of-life in delusional disorder: A mini-review. *Healthcare*. 2023, 11, 458.

doi: 10.3390/healthcare11040458 <https://www.mdpi.com/2227-9032/11/4/458>

Seeman, M.V.: Psychopharmacology and motherhood. *Parental Psychiatric Disorder: Distressed Parents and their Families*. 3rd Ed. Andrea Reupert, Darryl Maybery, Joanne Nicholson, Michael Göpfert, Mary V. Seeman (eds.), Ch. 20. Cambridge University Press. 2015. pp. 210-222.

<http://www.cambridge.org/ca/academic/subjects/medicine/mental-health-psychiatry-and-clinical-psychology/parental-psychiatric-disorder-distressed-parents-and-their-families-3rd-edition?format=HB>

Seeman, M.V., Becker, R.E., Greig, N.H.: Geriatric pharmacotherapy: Appraising new drugs for neurological disorders in older patients. (DeKosky ST, Asthana S, eds.) *Handbook of Clinical Neurology* (Aminoff, M.J., Boller, F., Swaab, D.F, series eds.): *Geriatric Neurology*. Vol. 167. Ch. 1 pp. 3-18. San Diego Elsevier BV. 2019. ISBN: 978-0-12-804766-8 doi: [10.1016/B978-0-12-804766-8.00001-7](https://doi.org/10.1016/B978-0-12-804766-8.00001-7) <https://www.elsevier.com/books/geriatric-neurology/dekosky/978-0-12-804766-8>

Seeman, M.V., Remington, G.: Commentary on Antipsychotic agents: elucidation of their mode of action, by A. Carlsson. *The Nervous System, Discoveries in Pharmacology*. Volume 1. Parnham M., Page C., Bruinvels J., eds. Elsevier. Ch. 4A, 2023, pp. 101-106. ISBN 9780323855198 doi: 10.1016/B978-0-323-85519-8.00001-8 <https://www.sciencedirect.com/science/article/pii/B9780323855198000018>